DataMEDS AI Stock Soars 253% After $1.5M Helomics Acquisition Enters $40B Cancer Diagnostics Market

DataMEDS AI Completes Strategic Helomics Acquisition

DataMEDS AI (NASDAQ:MEDS) completed the acquisition of Helomics Corporation, an AI-driven cancer diagnostics laboratory, from Axe Compute Inc. (NASDAQ:AGPU) for $1.5 million1

1

2

2

. The transaction, structured through common shares and an acquisition note, marks DataMEDS AI's strategic expansion into oncology and positions the company to improve patient outcomes in underserved markets. Shares of NASDAQ:MEDS surged 253.70% to $5.73 on Wednesday, reaching a new 52-week high as investors responded to the completed deal1

1

. The stock had already jumped 66.04% to $2.68 in pre-market trading following the announcement3

3

.

Deal Structure Delivers Immediate Value

Under the Helomics acquisition agreement, DataMEDS AI received a CLIA/CAP-certified clinical laboratory with all equipment, the Predictive Oncology contract research organization central lab services business, and $1.5 million in cash2

2

4

4

. The acquired entity carries zero third-party debt and no outstanding accounts payable outside of regular monthly operating expenses, providing operational capital to drive expansion1

1

. This clean balance sheet allows DataMEDS AI to focus resources on integrating Helomics into its healthcare ecosystem without the burden of inherited liabilities.

Helomics, a Pittsburgh-based functional precision medicine oncology platform, applies artificial intelligence to real-world tumor data to support drug discovery and cancer treatment decisions2

2

4

4

. The business represents the final operating unit from Axe Compute's former identity as Predictive Oncology Inc., prior to its name change in December 20252

2

.

Targeting the $40 Billion Cancer Diagnostic Market

The transaction thrusts DataMEDS AI into the $40 billion U.S. cancer diagnostic and treatment market, broadening its clinical focus beyond GLP-1 agonist side-effect management and long COVID care1

1

3

3

. Gerald Commissiong, Interim Co-CEO of DataMEDS AI, stated: "We are thrilled to have completed this strategic transaction that thrusts DataMEDS into the field of oncology, where we know there is a tremendous need to improve patient outcomes, especially in rural areas"2

2

. This focus on rural areas addresses a critical gap in cancer care access and positions the precision oncology CRO business to serve underserved populations.

Under DataMEDS AI's ownership, Helomics is expected to expand its capabilities beyond tumor molecular profiling and chemosensitivity testing, moving into cancer screening and molecular profiling, traditional CLIA laboratory services, and optimized nutritional support for cancer patients2

2

. This expansion leverages AI cancer diagnostics to challenge existing standards of care in difficult-to-treat chronic conditions.

Market Response and Future Implications

The stock surge reflects investor confidence in DataMEDS AI's ability to integrate the AI-driven cancer diagnostics laboratory into its existing healthcare technology platform. With a market capitalization of approximately $5 million, the company now operates across multiple healthcare verticals including technology, pharmacy, and telemedicine business units3

3

. Chris Miglino, CEO of Axe Compute, noted that his company was pleased to maintain an equity stake in "the future of AI Helomics" while focusing resources on scaling core GPU-as-a-Service infrastructure1

1

.

Watch for DataMEDS AI's Form 8-K filing with the U.S. Securities and Exchange Commission, which will provide additional transaction details4

4

. The integration of Helomics' precision oncology capabilities with DataMEDS AI's existing EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts could create synergies that accelerate drug discovery and personalized cancer treatment approaches. Investors should monitor how effectively the company deploys the $1.5 million in acquired cash to scale operations and whether the CLIA/CAP-certified clinical laboratory can generate sustainable revenue in competitive oncology diagnostics markets.